Esperion (ESPR) released a press release today stating that their phase 3 CLEAR study met its primary endpoint (mortality benefit of at least 15%) yet the stock was down 15%. I don’t get why. And before anyone says that a positive trial outcome was already “baked” in to the stock price, that clearly wasn’t the case here. The drug and company have struggled since initial FDA approval in 2020.
https://www.globenewswire.com/news-release/2022/12/07/2569280/0/en/Esperion-Announces-CLEAR-Cardiovascular-Outcomes-Trial-of-NEXLETOL-bempedoic-acid-Meets-Primary-Endpoint.html
